Effect of Hyoscine- Bromide on Duration of the First Stage of Labor
NCT ID: NCT06056869
Last Updated: 2023-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2023-09-27
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Hyoscine Butylbromide on Shortening of First and Second Stages of Labor
NCT02839213
Hyoscine Butyl Bromide for Management of Prolonged Labor
NCT01854073
Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women
NCT03055390
Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae
NCT02824679
The Effect of Hyoscine Butyl Bromide on the First Stage of Labor in Term Pregnancies
NCT00409890
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
buscopan group
will receive 2 ml (40 mg) of hyoscine butylbromide
hyoscine butylbromide
will be given during first stage of labor intravenously
control group
will receive 2 ml of normal saline
normal saline
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hyoscine butylbromide
will be given during first stage of labor intravenously
normal saline
placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Singleton pregnancy.
3. Presenting by the vertex.
4. Gestational age between 37 and 42 weeks
5. In active phase of labor with a cervical dilatation between 4-5 cm, with either intact membranes or spontaneous rupture of membranes for less than 12 h
Exclusion Criteria
2. Malpresentation.
3. Antepartum hemorrhage.
4. Labor induction
5. Contraindication to vaginal delivery.
6. Contraindication to hyoscine.
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maii Nawara
Role: PRINCIPAL_INVESTIGATOR
Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University maternity hospital
Cairo, Cairo/القاهرة, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS 503/2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.